Drug Shortage Report for AMPICILLIN SODIUM FOR INJECTION, USP
| Report ID | 162846 |
| Drug Identification Number | 01933353 |
| Brand name | AMPICILLIN SODIUM FOR INJECTION, USP |
| Common or Proper name | AMPICILLIN SODIUM INJ |
| Company Name | TEVA CANADA LIMITED |
| Market Status | MARKETED |
| Active Ingredient(s) | AMPICILLIN |
| Strength(s) | 2G |
| Dosage form(s) | POWDER FOR SOLUTION |
| Route of administration | INTRAVENOUS INTRAMUSCULAR INTRAVENOUS INTRAMUSCULAR |
| Packaging size | 10 |
| ATC code | J01CA |
| ATC description | BETA-LACTAM ANTIBACTERIALS, PENICILLINS |
| Reason for shortage | Disruption of the manufacture of the drug. |
| Anticipated start date | |
| Actual start date | 2022-06-16 |
| Estimated end date | 2023-02-28 |
| Actual end date | 2023-04-27 |
| Shortage status | Resolved |
| Updated date | 2023-04-28 |
| Company comments | |
| Health Canada comments | |
| Tier 3 Status | No |
| Contact Address | 30 NOVOPHARM COURT TORONTO, ONTARIO CANADA M1B 2K9 |
| Company contact information |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
| Version Number | Date Updated | Language | |
|---|---|---|---|
| v2 | 2022-06-16 | French | Compare |
| v1 | 2022-06-16 | English | Compare |